Ionis Pharmaceuticals’ shares fell >20% after its Phase-3 CARDIO-TTRansform trial missed the primary endpoint. Separately, Levi & Korsinsky is investigating potential securities law violations, adding an overhang on investor confidence and potential legal exposure.
Ionis Pharmaceuticals’ shares fell >20% after its Phase-3 CARDIO-TTRansform trial missed the primary endpoint. Separately, Levi & Korsinsky is investigating potential securities law violations, adding an overhang on investor confidence and potential legal exposure.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
strongly negative
Sentiment Score
-0.65
Ticker Sentiment
